Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition. The RESILIENCE trial will use CMR as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study.
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.
How Does Your Heart Relate to Cancer? This question was at the center of two recent RESILIENCE outreach events held at the Spanish National Center for Cardiovascular Research (CNIC), where science met curiosity and dialogue. Science and Innovation Week On November 11, RESILIENCE hosted an open workshop during Madrid’s Science
In the framework of the European Researchers’ Night and the Science and Innovation Week to be celebrated in Madrid on September and November, our team RESILIENCE has planned two activities open to the public from 14 to 18 years old upon registration. We are organizing two workshops under the title
The RESILIENCE project was featured at the Annual Congress of the European Hematology Association (EHA), held in Milan from June 12 to 15th. The session focused on quality of life in oncology patients, with special attention to individuals living with hematological malignancies such as lymphomas and leukemias. Two researchers from
On June 20th we participated on the ESC Cardio-Oncology 2025 in Florence, organised by the ESC Council of Cardio-Oncology, an event that brings together European & non-European specialists from Cardiology, Oncology, Hematology, Radiotherapy and related disciplines. The conference covers a wide range of topics to improve the prevention, diagnosis, treatment
In March, the RESILIENCE project passed the halfway point of its recruitment process, with more than 300 people participating in this clinical trial, which aims to reduce the incidence of heart failure in cancer survivors. Patients are distributed among the 22 hospitals in the six countries participating in this multinational
At RESILIENCE, we believe it’s important to provide timely updates on the project, which is why we work to keep our social media channels up to date. You can find information about the new hospitals that have joined the project in Spain and the rest of Europe; the articles we
